New Customers Get 10% Off – Use Code: LUX10

GHRH Secretagogue

CJC

5.0 Reviews

CJC/Ipa Blend

A synthetic growth hormone–releasing hormone (GHRH) analog that stimulates natural GH secretion, studied for its effects on hormone regulation and pulsatile release patterns in research models. Premium Research Peptide.

Original price was: $64.99.Current price is: $58.49.

2 Day FAST Shipping

99%+ Purity Tests

Ships from USA

USA Lab Tested

We accept :

Certificate of Analysis

Third Party Tested by Freedom Diagnostics

How CJC Works

The Science, Simplified

Sustained GHRH Receptor Agonism

CJC-1295 is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH). While the “No DAC” version mimics the natural, short pulses of growth hormone, the DAC (Drug Affinity Complex) version is designed for a “steady-state” release.
Key insight: By binding to albumin in the bloodstream, CJC-1295 with DAC extends its half-life to approximately 6 to 8 days. In clinical studies, a single administration was shown to keep plasma Growth Hormone (GH) levels elevated by 2- to 10-fold for a week or longer.
GE
Primary

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

COL
Strongest

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

Cu²⁺
Supportive

Gene Expression

Epigenetic Modulation

Upregulates 59% of affected genes Activates 47 DNA repair genes Suppresses inflammatory pathways

The GH-IGF-1 Axis Elevation

The primary goal of this peptide in research is the sustained elevation of Insulin-like Growth Factor 1 (IGF-1).

Key insight: Unlike short-acting secretagogues, the DAC version creates a “bleed” effect of growth hormone. Research indicates that with multiple doses, IGF-1 levels can remain significantly elevated for up to 28 days, providing a consistent anabolic environment for tissue repair and muscle protein synthesis.

Protection Against Enzymatic Degradation

CJC-1295 incorporates four specific amino acid substitutions that protect it from DPP-4 cleavage, the enzyme primarily responsible for breaking down natural GHRH.

Key insight: This structural reinforcement ensures the peptide remains bioactive for much longer than native GHRH or Sermorelin. This allows researchers to study the long-term effects of GH elevation without the need for multiple daily administrations.

Wrinkle Reduction Comparison

Safety Profile from Research

What clinical studies report

CJC-1295 with DAC has been studied in Phase II clinical trials. While generally well-tolerated, its long-acting nature requires careful monitoring in research protocols.

🧿 Common Digestive Issues

25%

Injection Site Flushing

mild

15%

Water Retention

mild

10%

Lethargy

mild

Safety Advantage

High Selectivity

  • No "Shutdown": Unlike exogenous HGH (Growth Hormone), CJC-1295 stimulates the body's own pituitary gland. This preserves the natural negative feedback loop, reducing the risk of permanent hormonal suppression.
  • Preserved Pulsatility: Even with the "steady-state" release of the DAC version, the pituitary gland still maintains some level of natural pulsatile release, which is seen as a safer alternative to constant synthetic HGH.
  • Metabolic Benefits: Research models often show improved insulin sensitivity and lipid profiles, provided that GH levels are kept within a physiological research range.

📊 Discontinuation Rates

🚫 Trial Exclusions

⚡ Regulatory Status

💡 Researcher Notes

Compound Information

Technical specifications for this long-acting GHRH analog

🔬 Molecular Profile

What Is CJC?

Other names

CJC-1295 with DAC

Peptide Type

GHRH Analog (Tetrasubstituted)

Molecular Weight

~3367.9 Da

CAS Number

863288-34-0

Sequence

Modified GHRH (1-29) + DAC

🧊 Storage Requirements

Stability Information

Lyophilized (powder)

Store at -20°C

(Stable for 24 months).

Reconstituted

Store at 2-8°C;

use within 14-21 days.

Light Sensitive

Store in a dark environment

to prevent degradation.

📋 Blend Information

Development History

Discovery

ConjuChem Biotechnologies

Half-Life

~8 Days (Extended by Albumin binding)

US Status

Investigational Research Compound

WADA Status

Banned in all professional sports

Frequently Asked Questions

Common questions about CJC

The main difference is the frequency of administration. CJC-1295 No DAC (also known as Mod GRF 1-29) has a half-life of about 30 minutes and requires multiple daily doses. CJC-1295 with DAC has a half-life of 8 days, meaning it only needs to be administered once or twice a week in a research setting to maintain high GH levels.
While it can be studied alone, many researchers pair it with a GHRP like Ipamorelin. CJC-1295 acts as the "gas pedal" for GH production, while Ipamorelin acts as the "trigger" for the release. Together, they create a synergistic effect that significantly amplifies GH output.
DAC stands for Drug Affinity Complex. It is a chemical tail (Nɛ-maleimidopropionyl-Lysine) that allows the peptide to hitch a ride on albumin, a common protein in your blood. This prevents the kidneys from filtering it out quickly, which is why it stays active for so long.
Yes, this is a term used in research to describe the constant, elevated background level of Growth Hormone. While this is highly effective for fat loss and muscle repair, some researchers prefer the "No DAC" version because it more closely mimics the natural "up and down" spikes of the human body.
No. It reached Phase II clinical trials for growth hormone deficiency but is currently classified as an investigational research compound. It is not approved for human use or as a medical treatment.

Sources & References

Peer-reviewed research

Journal of Clinical Endocrinology & Metabolism

Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults

2006

Teichman SL, Neale A, Lawrence B et al.

View Source

European Journal of Endocrinology

Ipamorelin, the first selective growth hormone secretagogue

1998

Raun K, Hansen BS, Johansen NL et al.

View Source

Journal of Clinical Endocrinology & Metabolism

On the actions of the growth hormone-releasing hexapeptide, GHRP

1991

Bowers CY, Reynolds GA, Durham D et al.

View Source

Translational Andrology and Urology

A Review of Growth Hormone Secretagogues

2018

Sigalos JT, Pastuszak AW

View Source

Translational Andrology and Urology

A Review of Growth Hormone Secretagogues

2018

Sigalos JT, Pastuszak AW

View Source
  • Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.

By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.

My Account
Follow Us
Linkedin X-twitter Icon-instagram-1 Facebook-square